GlassScriptPhysician profile
Collette Munster Wagner
NPI 1316537673
$1,019.38
in general payments reported to CMS, 2019-2025
15 companies · $80.06 in 2025
The $80.06 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $204 · 2023: $401 · 2024: $138 · 2025: $80.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $309.19 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $221.14 | 2021-2023 | Quillichew Er, Quillivant, Dyanavel Xr |
| Noven Therapeutics, LLC | $89.73 | 2023-2024 | Xelstrym |
| Corium, LLC | $79.94 | 2022-2024 | Azstarys |
| Sanofi Pasteur INC. | $58.60 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $48.48 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $44.31 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $33.82 | 2023 | Ycanth |
| Pfizer INC. | $32.68 | 2021 | |
| Vertical Pharmaceuticals, LLC | $19.93 | 2025 | Relexxii |
| Seqirus USA INC | $19.58 | 2023 | Flucelvax Quadrivalent |
| Cranial Technologies, INC | $17.92 | 2024 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $17.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.00 | 2024 | |
| Genentech USA, INC. | $9.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collette Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.